INTRODUCTION
Mononuclear phagocytes play a central role in the initiation and resolution of innate and adaptive immune responses. They comprise several populations of monocytes, macrophages, and dendritic cells (DCs), which are classically defined by their phenotype and ontogeny (Guilliams et al., 2014) . Monocytes are very plastic cells and can differentiate into cells displaying typical features of macrophages or DCs, referred to as monocyte-derived macrophages (mo-Mac) and monocyte-derived DCs (mo-DC). This phenomenon has been described in vitro and in vivo, in both mouse and human (Jakubzick et al., 2017; Coillard and Segura, 2019; Ginhoux and Guilliams, 2016) . Recently, high-resolution single-cell technologies have revealed a new subset of blood DCs, termed DC3, displaying a mixed transcriptomic profile of classical DC (cDC) and monocyte genes (Bakdash et al., 2016; Dutertre et al., 2019; Villani et al., 2017) , reminiscent of that of mo-DC (Segura et al., 2013; Goudot et al., 2017) . Whether blood DC3 represent circulating mo-DC has been unclear.
Accumulating evidence suggests that monocyte-derived cells are involved in the pathogenesis of autoimmune and chronic inflammatory diseases (Coillard and Segura, 2019) . However, their characterization in inflamed tissues is complicated by the promiscuous expression of numerous phenotypic markers, shared in particular with macrophages and cDCs. More specific markers are needed in order to advance our understanding of the respective properties of macrophages, cDCs, and mo-DC, and ultimately to allow the manipulation of these cells for therapeutic strategies.
To identify novel markers for human mo-DC, we have used a synthetic library of humanized llama single domain antibodies. We identified one antibody, recognizing surface LSP-1, that stains specifically mo-DC, but not monocytes, macrophages, cDCs, or DC3.
RESULTS
In order to identify novel surface markers for human naturally occurring mo-DC, we set up a phage display screen using a synthetic library of humanized llama single domain antibodies (termed VHH) . We have previously shown that peritoneal ascites from patients with cancer contain a population of mo-DC (Segura et al., 2013; Tang-Huau et al., 2018) . Cells from tumor ascites were separated into DCs and all other cells (non-DCs), including tumor cells, macrophages, T cells, and other immune cells. The library was first depleted for phages binding to non-DCs, then phages binding to ascites DCs were screened (Figure 1A) . For subsequent studies, we produced the VHH of interest with a human Fc region containing a streptavidin-binding peptide. Using this strategy, we identified a VHH antibody, termed ''D4,'' that stains ascites DCs but not macrophages from the same samples ( Figure 1B ). We have recently reported a culture model allowing the generation of in vitro counterparts of naturally occurring mo-DC and mo-Mac, by culturing CD14 + monocytes with M-CSF, IL-4, and TNFa (Goudot et al., 2017) . In this model, the VHH D4 stained mo-DC but not mo-Mac ( Figure 1C ). We have also shown that the classical model of culturing monocytes with GM-CSF and IL-4 generates mo-DC that do not closely resemble the ones found in vivo in inflammatory fluids (Goudot et al., 2017) . Consistent with this, the VHH D4 did not stain mo-DC generated with GM-CSF and IL-4 ( Figure 1C ).
We then sought to address whether the VHH D4 could also stain other myeloid cells, in particular cDCs. We first used the VHH D4 on cells isolated from human tonsils. We have previously shown using single-cell RNA sequencing (RNA-seq) analysis that tonsils contain cDC1 (CD141 high CD1c À DCs) and cDC2 (CD141 low CD1c + DCs), but no population of mo-DC (Durand et al., 2019) . There was no significant staining of VHH D4 on cDC1, cDC2, or tonsil macrophages (Figure 2A ). This result suggests that the VHH D4 is specific of mo-DC and does not stain cDCs.
To extend these observations, we stained peripheral blood cells. There was no significant staining on plasmacytoid DCs (pDC), B cells, granulocytes, NK cells, or T cells ( Figure 2B ). We further dissected VHH D4 staining on myeloid cells ( Figure 2C ). Blood monocytes comprise three subpopulations defined by their expression of CD16 and CD14. In addition, it has recently been shown that blood CD1c + DCs are heterogeneous and comprise CD1c + CD14 À CD163 À DCs (bona fide cDC2) and CD1c + CD14 + CD163 + DCs, termed DC3 (Alcantara-Hernandez et al., 2017; Bakdash et al., 2016; Dutertre et al., 2019; Villani et al., 2017) . The VHH D4 did not show a significant staining on blood monocytes, cDC2, DC3, or other CD19 À HLA-DR + cells ( Figure 2C ). These results confirm that VHH D4 does not recognize cDCs or other blood leukocyte populations.
To determine the target of VHH D4 on the surface of mo-DC, we performed immuno-precipitation followed by proteomics mass spectrometry, using in vitro-generated mo-DC (cultured with M-CSF, IL-4, and TNFa) as a source of material. Mass spectrometry identified only one protein: Lymphocyte-Specific Protein 1 (LSP-1), a protein of predicted molecular weight of 60 kDa. To validate this result, we performed immuno-precipitation with VHH D4 on in vitro-generated mo-DC and mo-Mac and revealed the immuno-precipitated proteins using streptavidin ( Figure 3A ) or a commercial anti-LSP-1 antibody ( Figure 3B ). Both methods showed the same band around 55 kDa, only in immuno-precipitated material from mo-DC. This observation confirms that the VHH D4 binds LSP-1.
LSP-1 is an F-actin binding protein reported to be expressed in all leukocytes (Pulford et al., 1999) . Using our previously generated transcriptomic data (Goudot et al., 2017) , we confirmed that LSP1 was expressed at similar levels in ascites mo-DC; ascites macrophages; in vitro mo-DC and mo-Mac generated with M-CSF, IL-4, and TNFa; in vitro mo-DC generated with GM-CSF and IL-4; and blood monocytes ( Figure 4A ). Using transcriptomic data from the Human Cell Atlas, we also observed that LSP1 was expressed in all blood leukocytes, with myeloid cells displaying the highest levels ( Figure 4B ). To confirm the intracellular expression of LSP-1, we performed flow cytometry on permeabilized cells using either a commercial anti-LSP1 antibody or VHH D4. Although the commercial anti-LSP1 did not show any surface staining (including on mo-DC), it detected intracellular LSP1 in blood myeloid cells and in vitro-generated mo-DC and mo-Mac ( Figure 4C ). By contrast, VHH D4 did not stain intracellular LSP1 in blood myeloid cells or mo-Mac Peripheral blood myeloid cells were also analyzed (monocytes and cDC2). Cells were stained with a commercial anti-LSP-1 antibody (C) or VHH D4 (D), with membrane permeabilization (intracellular) or not (surface). Gray shaded histograms are fluorescence-minus-one controls. Representative of five (blood) or six (in vitro-generated) individual donors. and mo-DC ( Figure 4D ). These results suggest that VHH D4 recognizes a surface epitope of LSP-1 that is specifically expressed by mo-DC.
DISCUSSION
Using a synthetic library of humanized llama single domain antibodies, we have identified one antibody, recognizing LSP-1, that is specific for human mo-DC and distinguishes them from monocytes, macrophages, cDCs, or DC3.
LSP-1 has been shown so far to reside on the cytoplasmic side of the plasma membrane (Klein et al., 1989) . After membrane permeabilization, LSP-1 can be detected by flow cytometry, consistent with previous work (Pulford et al., 1999) . Because VHH D4 stains mo-DC without membrane permeabilization, our results suggest the existence of an extra-cellular domain of LSP-1 specifically in mo-DC. The VHH D4 stains both mo-DC found in vivo in tumor ascites and generated in vitro with M-CSF, IL-4, and TNFa, indicating that the expression of a surface domain of LSP-1 is not due to the inflammatory micro-environment, but rather could be the result of a mo-DC core transcriptional program. Whether surface LSP-1 results from alternative splicing or another post-transcriptional mechanism remains open for future investigation.
DC3 express a mixed transcriptional program with hallmark cDC2 genes (such as FCER1A, CD1C, CLEC10A) as well as typical monocyte genes (such as S100A8, S100A9, VCAN) (Bakdash et al., 2016; Dutertre et al., 2019; Villani et al., 2017) , raising the question of their ontogeny, in particular whether DC3 correspond to circulating mo-DC. Our results add to different lines of evidence suggesting that DC3 are distinct from mo-DC. Blood cDC2 and DC3, but not monocytes, were increased upon injection of Flt3ligand to patients with lymphoma (Dutertre et al., 2019) . In addition, in vitro differentiation assays and analysis of an allelic series of human IRF8 deficiency suggested that DC3 and monocytes derive from a common progenitor but along distinct differentiation pathways (Cytlak et al., 2019) . Here, we did not observe a significant staining of VHH D4 on blood DC3, showing that the phenotype of DC3 is distinct from that of ascites mo-DC. This is consistent with the hypothesis that DC3 do not represent circulating blood mo-DC.
Together with our previous phenotypic characterization of mo-DC (Goudot et al., 2017) and recent singlecell analysis of blood cDC2, DC3, and monocytes (Dutertre et al., 2019; Villani et al., 2017) , our work enables a more precise phenotypic definition of human DC subsets. cDC2 can be defined as CD88 À CD14 À CD1c + FcεRI + CD226 À CD163 À sLSP-1 -, DC3 as CD88 À CD14 + CD1c + FcεRI + CD226 À CD163 + sLSP-1 À , and mo-DC as CD88 low CD14 + CD1c + FcεRI + CD226 + CD163 À sLSP-1 + .
Mo-DC have been identified in several inflammatory contexts in human tissues (Coillard and Segura, 2019) . In cancer, the picture is less clear as DCs displaying a phenotype consistent with both mo-DC and DC3 have been reported in colorectal, breast, and lung tumors (Laoui et al., 2016; Lavin et al., 2017; Michea et al., 2018) . DC3 are increased in the blood of patients with melanoma (Bakdash et al., 2016) and systemic lupus erythematosus (Dutertre et al., 2019) , whereas blood DC3 infiltrate the lung alveolar space upon LPS-induced acute inflammation (Jardine et al., 2019) . The respective role of these two DC subtypes in cancer or inflammation remains elusive. Our findings will pave the way for a better characterization of DC3 and mo-DC in pathological settings, ultimately allowing their manipulation for therapeutic strategies.
Limitations of the Study
In this work, we have identified one antibody (VHH D4) that is specific for human mo-DC present in ascites or derived in vitro from monocytes using a combination of M-CSF, IL-4, and TNFa. Further work is needed to address whether VHH D4 also stains the mo-DC that have been described in other human tissues, such as skin, lung, or gut. In addition, complementary markers, such as defined in the Discussion, should be used for the accurate identification of myeloid cells in human tissues.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. According to French Public Health Law (article L1121), written consent and IRB approval are not required for human non-interventional studies.
Cell isolation. Tonsil samples were digested as described previously (Durand and Segura, 2016) . In brief, samples were cut into small fragments, digested with 0.1 mg mL -1 Liberase TL (Roche) in the presence of 0.1 mg mL -1 DNAse (Roche) for 40 minutes at room temperature before addition of 10 mM EDTA. Cells were filtered on a 40 µm cell strainer (BD Falcon) and
washed. Light density cells were isolated by centrifugation on a Ficoll gradient (Lymphoprep, Greiner Bio-One). DCs and macrophages were enriched by depletion of cells expressing CD3, CD15, CD19, CD56 and CD235a using antibody-coated magnetic beads (Miltenyi). Peripheral Blood Mononuclear Cells (PBMC) were prepared by centrifugation on a Ficoll gradient. Blood CD14 + monocytes were isolated from healthy donors' PBMC by positive selection using anti-CD14-coated magnetic beads according to manufacturer's instructions (Miltenyi). DCs and macrophage populations from ascites were isolated after cell sorting on a FACSAria instrument.
Ascites DCs were gated as HLA-DR + CD11c + CD1c + CD16 -.
Cell culture. Blood monocytes (1´10 6 cells mL -1 ) were cultured for 5 days in RPMI-Glutamax medium (Gibco) supplemented with antibiotics (penicillin and streptomicin) and 10% FCS in the presence of 100 ng mL -1 M-CSF (Miltenyi), 5 ng mL -1 IL-4 (Miltenyi) and 5 ng mL -1 TNF-a (Miltenyi), or 100 ng mL -1 GM-CSF (Miltenyi) and 5 ng mL -1 IL-4 (Miltenyi). In some experiments, mo-DC and mo-Mac were purified by cell sorting on a FACSAria instrument.
Mo-DC were gated as CD1a + CD16and mo-mac as CD1a -CD16 + .
Phage display screening. A synthetic phage display library of humanized llama single domain antibodies (NaLi-H1 library) was used as described to select binders.
Screening of positive clones was performed using 100 µL of supernatant (80 µL phages + 20 µL PBS/human serum 1%) incubated for 1 h on ice with 1´10 5 cells from tumor ascites.
After washing, phage binding on ascites cells was detected by flow cytometry using an antibody against M13, and ascites DCs were gated as HLA-DR + CD11c + CD1c + CD16and ascites macrophages as HLA-DR + CD11c + CD1c -CD16 + .
Western blot. Cells were lysed in RIPA buffer (Thermo Scientific) supplemented with cOmplete Mini EDTA-free protease inhibitor cocktail (Roche). Post-nuclear lysates were resolved by SDS-PAGE using 4-12% BisTris NuPAGE gels (Invitrogen) and proteins were transferred to membranes (Immunoblot PVDF membranes, Bio-Rad). Membranes were stained with anti-LSP1 (clone TPD153, Novus Biologicals) or streptavidin-HRP staining (Pierce).
Flow cytometry. For the analysis of tonsil cells, tonsil CD14 + macrophages were gated as HLA-DR + CD11c + CD14 + , tonsil cDC1 as HLA-DR + CD11c + CD14 -CD1c -CD141 + and tonsil cDC2 as HLA-DR + CD11c + CD14 -CD1c + . For the analysis of blood cells, B cells were gated as HLA-DR + CD19 + , pDC as HLA-DR + CD19 -CD11c -CD123 + , granulocytes as HLA-DR -CD19 -SSC high CD16 + , NK cells as HLA-DR -CD19 -CD14 -SSC low CD16 + , T cells as HLA-DR -CD19 -CD14 -SSC low CD16 -, CD16 + monocytes as HLA-DR + CD19 -CD16 + CD14 -, CD16 + CD14 + monocytes as HLA-DR + CD19 -CD16 + CD14 + , CD14 + monocytes as HLA-DR + CD19 -CD16 -CD14 + CD1c -, cDC2 as HLA-DR + CD19 -CD16 -CD14 -CD1c + , DC3 as HLA-DR + CD19 -CD16 -CD14 int CD1c + .
